drugset

drugset / Trial / NCT01419041

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

NCT01419041 ↗

Phase 1 Completed 16 enrolled Pfizer

RandomizedParallel-groupOpen-labelBasic science

Summary

The present study is being conducted to evaluate whether or not severe renal impairment has an effect on crizotinib Pharmacokinetics.

Timeline

Start: 2011-11
Primary completion: 2012-08
Completion: 2012-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Crizotinib	Small molecule	250 mg	Oral

Indications